Summary
In order to assess the etiologic role of hepatitis C virus (HCV) as well as hepatitis B virus (HBV) in the etiology of HCC, we compared the prevalence of HCV-related antibodies (anti-C100-3, anti-CP9, anti-CP10) and HBV-related markers (HBsAg, anti-HBs, anti-HBc) in sera of patients with liver cirrhosis (LC) with (n=62) and without (n=54) hepatocellular carcinoma (HCC). In HBsAg-negative cases, at least one HCV-related marker (including HCV RNA) was detected in 92.3% (48/52) of HCC cases and in all of the 44 LC cases without HCC, with no significant difference between these two groups. In HBsAg-positive cases, the prevalence of either one of these HCV-related markers was 40.0% (4/10) both in patients with and without HCC, and there was no significant difference between these two groups. Moreover, in HBsAg-negative cases and 11 cases of positive HCV-related markers, the prevalence of anti-HBs and/or anti-HBc was significantly higher in LC patients with HCC (85.4%) than those without HCC (43.2%, P<0.001). These results show a high prevalence of hepatitis B and C viral markers in Japanese patients with HCC and further indicate that previous HBV infection is a risk factor in the occurrence of HCC in HBsAg-negative LC and LC with positive HCV-related markers.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Kim CM, Koike K, Saito I, et al. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991;351:317–320.
Choo Q-L, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a bloodborne non-A non-B viral hepatitis genome. Science 1989;244:359–362.
Kuo G, Choo Q-L, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of human non-A non-B hepatitis. Science 1989;244:362–364.
Katkov WN, Cody H, Evans AA, et al. The role of hepatitis C virus (HCV) in chronic liver disease, (abstr.) Hepatology 1989;10:644.
Jeffers L, deMedina M, Hasan F, et al. Hepatitis C (HCV) associated idiopathic chronic hepatitis and cryptogenic cirrhosis, (abstr.) Hepatology 1989;10:644.
Alberti A, Tremolada F, Bortolotti F, et al. Anti-HCV and liver disease in Italy in the last 10 years, (abstr.) Hepatology 1989;10:644.
Bruix J, Barrera JM, Calvet X, et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989;ii:1004–1006.
Colombo M, Kuo G, Choo Q-L, et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989;ii:1006–1008.
Nishioka K, Watanabe J, Furuta S, et al. Antibody to the hepatitis C virus in acute hepatitis and chronic liver disease in Japan. Liver 1991;11:65–70.
Iino S, Kurai K, Hino K, et al. Detection of anti-HCV in patients with various liver disease. Acts Hepat Jap 1989;30:1643. (in Japanese)
The Liver Cancer Study Group of Japan. Survey and follow up study of primary liver cancer in Japan Report 8. Acts Hepat Jap 1988;29:1619–1626.
Okamoto H, Munekata E, Tsuda F, et al. Enzyme-linked immunosorbent assay for antibodies against the capsid protein of hepatitis C virus with a synthetic oligopeptide. Japan J Exp Med 1990; 60:223–233.
Okamoto H, Tsuda F, Machida A, et al. Antibodies against synthetic oligopeptides deduced from the putative core gene for the diagnosis of hepatitis C virus infection. Hepatology 1992;15:180–186.
Okamoto H, Okada S, Sugiyama Y, et al. Detection of hepatitis C virus RNA by a two stage polymerase chain reaction with two pairs of primers deduced from the 5′-noncoding region. Japan J Exp Med 1990;60:215–222.
Nishioka K, Watanabe J, Furuta S, et al. A high prevalence of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan. Cancer 1991;67:429–433.
Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990;12:671–675.
Chen D-S, Kuo GC, Sung JL, et al. Hepatitis C virus infection in an area hyperendemic for hepatitis B and CLD: The Taiwan experience. J Infect Dis 1990;162:817–822.
Ducreux M, Buffet C, Dussaix E, et al. Antibody to hepatitis C virus in hepatocellular carcinoma. Lancet 1990;335:301.
Yu MC, Tong MJ, Cousaget P, et al. Prevalence of hepatitis B and C viral markers in black and white patients with hepatocellular carcinoma in the United States. J Natl Cancer Inst 1990;82:1038–1041.
Wong DC, Diwan AR, Rosen L, et al. Non-specificity of anti-HCV test for seroepidemiological analysis. Lancet 1990;336:750–751.
Chiba J, Ohba H, Matsuura Y, et al. Serodiagnosis of hepatitis C virus (HCV) infection with an HCV core protein molecularly expressed by a recombinant baculovirus. Proc Natl Acad Sci USA 1991;88:4641–4645.
van der Poel CL, Cuypers HTM, Reesink HW, et al. Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoassay. Lancet 1991;337:317–319.
Mimms L, Vallari D, Ducharme L, et al. Specifity of anti-HCV ELISA assessed by reactivity to three immunodominant HCV regions. Lancet 1990;336:1590–1591.
Maupas P, Werner B, Larouze B, et al. Antibody to hepatitis-B core antigen in patients with primary hepatic carcinoma. Lancet 1975; ii:9–11.
Kubo Y, Okuda K, Hashimoto M, et al. Antibody to hepatitis B core antigen in patients with hepatocellular carcinoma. Gastroenterology 1977;72:1217–1220.
Okuda K, Nakashima T, Sakamoto K, et al. Hepatocellular carcinoma arising in noncirrhotic and highly cirrhotic livers: A comparative study of histopathology and frequency of hepatitis B markers. Cancer 1982;49:450–455.
Yuki N, Hayashi N, Kasahara A, et al. Hepatitis B virus markers and antibodies to hepatitis C virus in Japanese patients with hepatocellular carcinoma. Dig Dis Sci 1992;37:65–72.
Brechot C, Nalpas B, Courouce A-M, et al. Evidence that hepatitis B virus has a role in liver-cell carcinoma in alcoholic liver disease. N Engl J Med 1982;306:1384–1387.
Brechot C, Degos F, Lugassy C, et al. Hepatitis B virus DNA in patients with CLD and negative tests for hepatitis B surface antigen. N Engl J Med 1985;312:270–276.
Paterlini P, Gerken G, Nakajima E, et al. Polymerase chain reaction to detect hepatitis B virus DNA and RNA sequences in primary liver cancers from patients negative for hepatitis B surface antigen. N Egnl J Med 1990;323:80–85.
Kaneko S, Miller RH, Feinstone SM, et al. Detection of serum hepatitis B virus DNA in patients with chronic hepatitis using the polymerase chain reaction assay. Proc Natl Acad Sci USA 1989;86: 312–316.
Galloway DA, McDougall JK. The oncogenic potential of herpes simplex virus: Evidence for a “hit-and-run” mechanism. Nature 1983;302:21–24.
Sbolli G, Zanetti AR, Tanzi E, et al. Serum antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. J Med Virol 1990;30:230–232.
Jeng J-E, Tsai J.F. Hepatitis C virus antibody in hepatocellular carcinoma in Taiwan. J Med Virol 1991;34:74–77.
Simonetti RG, Cottone M, Craxi’ A, et al. Prevalence of antibodies to hepatitis C virus in hepatocellular carcinoma. Lancet 1989;ii: 1338.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tanaka, N., Chiba, T., Matsuzaki, Y. et al. High prevalence of hepatitis B and C viral markers in Japanese patients with hepatocellular carcinoma. Gastroenterol Jpn 28, 547–553 (1993). https://doi.org/10.1007/BF02776954
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02776954